SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DR. BOND who wrote (2835)11/26/1997 2:46:00 AM
From: Steve Childs  Read Replies (2) of 23519
 
This is not directed at you, agent 007, aka, Dr. Bond, it's directed to the PFE lovers: YOU GOT THE WRONG STOCK! If you really want a winner in big cap drug firms, buy LLY. Now THERE'S a winner. Better valuation, and their new drug for osteoporosis should be a blockbuster. Great pipeline. Pfizer's proper valuation is around $65. LLY's is also around $65-70. Look at the prices, and then pick one. I'd pick osteoporosis over impotence, since Lilly doesn't have a 'Vivus' competing against it, as PFE does, does it?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext